Physician profile
Eric Tatro
NPI 1558821827
$2,421.80
in general payments reported to CMS, 2019-2025
13 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $90.72 · 2023: $558 · 2024: $1,019 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.09 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.49 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $514.36 | 2022-2025 | Gattex, Entyvio, Eohilia |
| Janssen Biotech, INC. | $458.46 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $213.00 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $195.13 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $151.95 | 2023 | Rebyota |
| Cook Medical LLC | $147.80 | 2025 | Hemospray |
| Pfizer INC. | $69.27 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.20 | 2023 | Xifaxan |
| Gilead Sciences, INC. | $42.76 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.00 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $16.24 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tatro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.